Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma
Status:
Withdrawn
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Ridaforolimus has been tested in almost 2 dozen studies; however, it has not previously been
tested in combination with the standard of care chemotherapy for sarcoma as this study will.
We will be looking to see if Ridaforolimus given with SOC chemo (AIM or TG) is well tolerated
and to determine a Phase 2 dose.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio